HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
